CJC-1295 with DAC
PopularLong-acting growth hormone-releasing hormone analog with extended half-life
CJC-1295 with DAC (Drug Affinity Complex, 5mg) is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered for an extended duration of action. This modification allows the peptide to bind to serum albumin, dramatically extending its half-life from minutes to approximately 6-8 days. As a long-acting GHRH analog, CJC-1295 DAC provides sustained stimulation for the release of growth hormone (GH) from the pituitary gland.
- •Provides sustained GH elevation (6-8 day half-life) from single administration.
- •Preserves physiological pulsatile GH release patterns.
- •Elevates downstream Insulin-like Growth Factor-1 (IGF-1) levels.
- •Supports research into muscle protein synthesis and lean body mass.
- •Valuable for studying enhanced lipolysis and fat metabolism.
- •Facilitates long-term studies on GH physiology and metabolic adaptations.
- •Demonstrates synergistic potential when combined with GH secretagogues (GHRPs).
CJC-1295 DAC selectively binds to GHRH receptors on somatotroph cells within the anterior pituitary gland, activating G-protein coupled receptor signaling pathways. This receptor activation stimulates adenylyl cyclase, leading to increased cyclic AMP (cAMP) production, which subsequently triggers protein kinase A (PKA) and initiates the signaling cascade necessary for growth hormone synthesis and release. The critical Drug Affinity Complex (DAC) modification enables CJC-1295 to bind non-covalently to serum albumin. This binding establishes a circulating reservoir that slowly releases the active peptide over an extended period. This gradual release maintains elevated GH levels while crucially preserving the natural pulsatile secretion pattern. This pulsatile release enhances the amplitude and frequency of GH pulses, which is essential for maintaining optimal GH receptor sensitivity and avoiding desensitization, thereby mediating downstream effects such as hepatic IGF-1 production and subsequent anabolic and metabolic activity.
CJC-1295 with DAC is primarily utilized in studies investigating growth hormone physiology, regulation, and the effects of sustained GH elevation. Its extended half-life makes it particularly suitable for long-term investigations into aging, growth hormone deficiency, and metabolic adaptations, including body composition and energy expenditure research. Further applications include research into muscle protein synthesis, bone density, and skeletal health. The compound is also valuable for comparative studies against other GHRH analogs and for exploring synergistic combinations with GH secretagogues (e.g., GHRP-2, Ipamorelin) to achieve enhanced GH release dynamics. Researchers employ CJC-1295 DAC to model long-term GH effects, safety profiles, and the functioning of the pituitary-neuroendocrine system.
Based on research applications and synergistic mechanisms, this peptide is frequently combined with:
No reviews yet. Be the first to review CJC-1295 with DAC!
Have a question about CJC-1295 with DAC? Ask here and get answers from our team or other researchers.
Research Use Only
This product is sold strictly for research purposes only. It is not approved by the FDA for human consumption or medical use. Intended for laboratory and research applications by qualified researchers and institutions only.